U.S. FDA declines to approve Spectrum's lung cancer drug
Reuters
Published Nov 25, 2022 06:24AM ET
Updated Nov 25, 2022 05:31PM ET
(Reuters) -Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration (FDA) declined to approve its experimental lung cancer drug due to inadequate data, prompting the drugmaker to cut jobs.
The company said it will no longer focus on developing the drug, poziotinib, for treating non-small cell lung cancer (NSCLC) with a rare genetic mutation that affects 2%-4% of the cancer patients. It will instead explore strategic alternatives for it, such as partnerships with other drugmakers.
Spectrum's (NASDAQ:SPPI) shares fell 13.9% to 37 cents in premarket trading. They have fallen 42.5% since an expert panel to the FDA recommended against the drug's approval in September.
The panel of independent experts had raised concerns over the efficacy of the treatment compared to drugs for NSCLC without mutation such as Daiichi Sankyo and AstraZeneca (NASDAQ:AZN)'s Enhertu.
Nevada-based Spectrum said it will cut 75% of its research and development workforce and focus on its other cancer drug, Rolvedon. It had 164 employees as of Dec. 31, 2021.
Spectrum is working to shore up capital, through cost cuts, to support a wider launch for Rolvedon, which treats patients with chemotherapy-induced infections caused due to low levels of infection-fighting cells in the body.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.